Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Institut Gustave Roussy · Université Paris-Saclay · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,472
total citations
- FWCI
- 121.76
- Percentile
- 100%
- References
- 27
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Internal medicine
- Response Evaluation Criteria in Solid Tumors
- Oncology
- Cohort
- Mesothelioma
- Biomarker
No related works found for this paper.